162 related articles for article (PubMed ID: 37372475)
21. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
22. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
Moschos MM; Dettoraki M; Androudi S; Kalogeropoulos D; Lavaris A; Garmpis N; Damaskos C; Garmpi A; Tsatsos M
Anticancer Res; 2018 Jul; 38(7):3817-3824. PubMed ID: 29970501
[TBL] [Abstract][Full Text] [Related]
23. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Singh T; Prasad R; Katiyar SK
Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
27. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
28. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
29. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
[TBL] [Abstract][Full Text] [Related]
31. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
32. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Chao OS; Goodman OB
Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment.
Ouyang D; Zhang Y; Xu L; Li J; Zha Q; He X
Acta Biochim Biophys Sin (Shanghai); 2011 Jun; 43(6):487-95. PubMed ID: 21628505
[TBL] [Abstract][Full Text] [Related]
34. Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic
Vent-Schmidt RYJ; Wen RH; Zong Z; Chiu CN; Tam BM; May CG; Moritz OL
J Neurosci; 2017 Jan; 37(4):1039-1054. PubMed ID: 28490005
[TBL] [Abstract][Full Text] [Related]
35. In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line.
Sanaei M; Kavoosi F; Roustazadeh A; Shahsavani H
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2507-2510. PubMed ID: 30256044
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE
Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590
[TBL] [Abstract][Full Text] [Related]
37. Could valproic acid be an effective anticancer agent? The evidence so far.
Brodie SA; Brandes JC
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1097-100. PubMed ID: 25017212
[TBL] [Abstract][Full Text] [Related]
38. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
39. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM
Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950
[TBL] [Abstract][Full Text] [Related]
40. Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma.
Gu S; Tian Y; Chlenski A; Salwen HR; Lu Z; Raj JU; Yang Q
Anticancer Drugs; 2012 Nov; 23(10):1054-66. PubMed ID: 22863973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]